Difference between revisions of "Pictilisib (GDC-0941)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 5: | Line 5: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:PI3K alpha inhibitors]] | [[Category:PI3K alpha inhibitors]] | ||
[[Category:PI3K delta inhibitors]] | [[Category:PI3K delta inhibitors]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 23:17, 28 February 2020
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.